Role of renin-angiotensin system in inflammation, immunity and aging

Current Pharmaceutical Design

Volumn 18, Issue 7, 2012, Pages 963-970

  Capettini, Luciano S A ^a   Montecucco, Fabrizio ^b   Mach, François ^b   Stergiopulos, Nikos ^a   Santos, Robson A S ^c   da Silva, Rafaela F ^a,c  

^a EPFL   (Switzerland)

^b UNIVERSITY HOSPITAL   (Switzerland)

^c FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Aging; Ang II; Ang (1 7); Immune system; Inflammation; Renin angiotensin

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN I; ANGIOTENSIN II; CANDESARTAN; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; LISINOPRIL; LOSARTAN; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE; RENIN; SIRTUIN; SIRTUIN 1; SIRTUIN 3; SIRTUIN 7; VALSARTAN;

AGING; ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; CELL GROWTH; CELL MIGRATION; CYTOKINE PRODUCTION; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GLOMERULOSCLEROSIS; GROWTH INHIBITION; HUMAN; HYPERTENSION; IMMUNITY; IMMUNOMODULATION; INFLAMMATION; KIDNEY ALLOGRAFT; KIDNEY GRAFT REJECTION; MITOCHONDRION; MULTIPLE SCLEROSIS; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; TH1 CELL; TH17 CELL;

AGING; ANIMALS; AUTOIMMUNE DISEASES; HUMANS; INFLAMMATION; RENIN-ANGIOTENSIN SYSTEM;

EID: 84857136817     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212799436593     Document Type: Review

References (123)

1. Basso N, Terragno NA. History about the discovery of the reninangiotensin system. Hypertension 2001; 38: 1246-9.
2. Geara AS, Azzi J, Jurewicz M, Abdi R. The renin-angiotensin system: an old, newly discovered player in immunoregulation. Transplant Rev (Orlando) 2009; 23: 151-8.
3. Cassis P, Conti S, Remuzzi G, Benigni A. Angiotensin receptors as determinants of life span. Pflugers Arch 2011; 459: 325-32.
4. Unger T. The role of the renin-angiotensin system in the development of cardiovascular disease. Am J Cardiol 2002;89: 3A-9A; discussion 10A.
5. Benigni A, Cassis P, Remuzzi G. Angiotensin II revisited: new roles in inflammation, immunology and aging. EMBO Mol Med 2011; 2: 247-57.
6. Santos RA, Ferreira AJ. Angiotensin-(1-7) and the reninangiotensin system. Curr Opin Nephrol Hypertens 2007; 16: 122-8.
7. Abadir PM, Carey RM, Siragy HM. Angiotensin AT2 receptors directly stimulate renal nitric oxide in bradykinin B2-receptor-null mice. Hypertension 2003; 42: 600-4.
8. Iwai M, Chen R, Li Z, et al. Deletion of angiotensin II type 2 receptor exaggerated atherosclerosis in apolipoprotein E-null mice. Circulation. 2005;112: 1636-43.
9. Ardaillou R. Angiotensin II receptors. J Am Soc Nephrol 1999; 10 Suppl 11: S30-9.
10. Santos RA, Simoes e Silva AC, Maric C, et al. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci USA 2003; 100: 8258-63.
11. Ferreira AJ, Santos RA, Almeida AP. Angiotensin-(1-7): cardioprotective effect in myocardial ischemia/reperfusion. Hypertension 2001; 38: 665-8.
12. Ardaillou R, Chansel D. Synthesis and effects of active fragments of angiotensin II. Kidney Int 1997; 52: 1458-68.
13. Santos RA, Campagnole-Santos MJ, Andrade SP. Angiotensin-(1-7): an update. Regul Pept 2000; 91: 45-62.
14. Santos RA, Brosnihan KB, Chappell MC, et al. Converting enzyme activity and angiotensin metabolism in the dog brainstem. Hypertension 1988; 11: I153-7.
15. Lambert DW, Clarke NE, Turner AJ. Not just angiotensinases: new roles for the angiotensin-converting enzymes. Cell Mol Life Sci 2010; 67: 89-98.
16. Machado RD, Ferreira MA, Belo AV, Santos RA, Andrade SP. Vasodilator effect of angiotensin-(1-7) in mature and spongeinduced neovasculature. Regul Pept 2002; 107: 105-13.
17. Xu P, Costa-Goncalves AC, Todiras M, et al. Endothelial dysfunction and elevated blood pressure in MAS gene-deleted mice. Hypertension 2008; 51: 574-80.
18. Silva DM, Vianna HR, Cortes SF, Campagnole-Santos MJ, Santos RA, Lemos VS. Evidence for a new angiotensin-(1-7) receptor subtype in the aorta of Sprague-Dawley rats. Peptides 2007; 28: 702-7.
19. Lemos VS, Silva DM, Walther T, Alenina N, Bader M, Santos RA. The endothelium-dependent vasodilator effect of the nonpeptide Ang(1-7) mimic AVE 0991 is abolished in the aorta of masknockout mice. J Cardiovasc Pharmacol 2005; 46: 274-9.
20. Droge W. Free radicals in the physiological control of cell function. Physiol Rev. 2002; 82: 47-95.
21. Djordjevic VB, Zvezdanovic L, Cosic V. [Oxidative stress in human diseases]. Srp Arh Celok Lek 2008; 136 Suppl 2: 158-65.
22. Emerit I. Reactive oxygen species, chromosome mutation, and cancer: possible role of clastogenic factors in carcinogenesis. Free Radic Biol Med 1994; 16: 99-109.
23. Mantovani G, Macciò A, Madeddu C, et al. Reactive oxygen species, antioxidant mechanisms, and serum cytokine levels in cancer patients: impact of an antioxidant treatment. J Environ Pathol Toxicol Oncol 2003; 22: 17-28.
24. Oak JH, Youn JY, Cai H. Aminoguanidine inhibits aortic hydrogen peroxide production, VSMC NOX activity and hypercontractility in diabetic mice. Cardiovasc Diabetol 2009; 8: 65.
25. Laursen JB, Somers M, Kurz S, et al. Endothelial regulation of vasomotion in apoE-deficient mice: implications for interactions between peroxynitrite and tetrahydrobiopterin. Circulation 2001; 103: 1282-8.
26. Busse R, Fleming I. Endothelial dysfunction in atherosclerosis. J Vasc Res 1996; 33: 181-94.
27. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 2000; 87: 840-4.
28. Higashi Y, Noma K, Yoshizumi M, Kihara Y. Endothelial function and oxidative stress in cardiovascular diseases. Circ J 2009; 73: 411-8.
29. Perry JJ, Fan L, Tainer JA. Developing master keys to brain pathology, cancer and aging from the structural biology of proteins controlling reactive oxygen species and DNA repair. Neuroscience 2007; 145: 1280-99.
30. Fukuda K. [Progress of research in osteoarthritis. Involvement of reactive oxygen species in the pathogenesis of osteoarthritis]. Clin Calcium 2009; 19: 1602-6.
31. Walter A, Etienne-Selloum N, Brasse D, et al. Red wine polyphenols prevent acceleration of neovascularization by angiotensin II in the ischemic rat hindlimb. J Pharmacol Exp Ther 2009; 329: 699-707.
32. Pueyo ME, Gonzalez W, Nicoletti A, Savoie F, Arnal JF, Michel JB. Angiotensin II stimulates endothelial vascular cell adhesion molecule-1 via nuclear factor-kappaB activation induced by intracellular oxidative stress. Arterioscler Thromb Vasc Biol 2000; 20: 645-51.
33. Loot AE, Schreiber JG, Fisslthaler B, Fleming I. Angiotensin II impairs endothelial function via tyrosine phosphorylation of the endothelial nitric oxide synthase. J Exp Med 2009; 206: 2889-96.
34. Touyz RM, Schiffrin EL. Reactive oxygen species in vascular biology: implications in hypertension. Histochem Cell Biol 2004; 122: 339-52.
35. Chose O, Sansilvestri-Morel P, Badier-Commander C, et al. Distinct role of nox1, nox2, and p47phox in unstimulated versus angiotensin II-induced NADPH oxidase activity in human venous smooth muscle cells. J Cardiovasc Pharmacol 2008; 51: 131-9.
36. Touyz RM, Schiffrin EL. Ang II-stimulated superoxide production is mediated via phospholipase D in human vascular smooth muscle cells. Hypertension 1999; 34: 976-82.
37. An SJ, Boyd R, Zhu M, Chapman A, Pimentel DR, Wang HD. NADPH oxidase mediates angiotensin II-induced endothelin-1 expression in vascular adventitial fibroblasts. Cardiovasc Res 2007; 75: 702-9.
38. Shen WL, Gao PJ, Che ZQ, et al. NAD(P)H oxidase-derived reactive oxygen species regulate angiotensin-II induced adventitial fibroblast phenotypic differentiation. Biochem Biophys Res Commun 2006; 339: 337-43.
39. Feliers D, Gorin Y, Ghosh-Choudhury G, Abboud HE, Kasinath BS. Angiotensin II stimulation of VEGF mRNA translation requires production of reactive oxygen species. Am J Physiol Renal Physiol 2006; 290: F927-36.
40. Schieffer B, Luchtefeld M, Braun S, Hilfiker A, Hilfiker-Kleiner D, Drexler H. Role of NAD(P)H oxidase in angiotensin II-induced JAK/STAT signaling and cytokine induction. Circ Res 2000; 87: 1195-201.
41. Rodgers K, Xiong S, DiZerega GS. Effect of angiotensin II and angiotensin(1-7) on hematopoietic recovery after intravenous chemotherapy. Cancer Chemother Pharmacol 2003; 51: 97-106.
42. Suzuki H, Eguchi K, Ohtsu H, et al. Activation of endothelial nitric oxide synthase by the angiotensin II type 1 receptor. Endocrinology 2006; 147: 5914-20.
43. Peters J, Kranzlin B, Schaeffer S, et al. Presence of renin within intramitochondrial dense bodies of the rat adrenal cortex. Am J Physiol 1996; 271: E439-50.
44. Eggena P, Zhu JH, Sereevinyayut S, et al. Hepatic angiotensin II nuclear receptors and transcription of growth-related factors. J Hypertens 1996; 14: 961-8.
45. Eggena P, Zhu JH, Clegg K, Barrett JD. Nuclear angiotensin receptors induce transcription of renin and angiotensinogen mRNA. Hypertension 1993; 22: 496-501.
46. Robertson AL, Jr., Khairallah PA. Angiotensin II: rapid localization in nuclei of smooth and cardiac muscle. Science 1971; 172: 1138-9.
47. Gonzales S, Noriega GO, Tomaro ML, Pena C. Angiotensin-(1-7) stimulates oxidative stress in rat kidney. Regul Pept 2002; 106: 67-70.
48. Lakshmanan AP, Watanabe K, Thandavarayan RA, et al. Telmisartan attenuates oxidative stress and renal fibrosis in streptozotocin induced diabetic mice with the alteration of angiotensin-(1-7) mas receptor expression associated with its PPAR-gamma agonist action. Free Radic Res 2011; 45: 575-84.
49. Lavrentyev EN, Malik KU. High glucose-induced Nox1-derived superoxides downregulate PKC-betaII, which subsequently decreases ACE2 expression and ANG(1-7) formation in rat VSMCs. Am J Physiol Heart Circ Physiol 2009; 296: H106-18.
50. Dhaunsi GS, Yousif MH, Akhtar S, Chappell MC, Diz DI, Benter IF. Angiotensin-(1-7) prevents diabetes-induced attenuation in PPAR-gamma and catalase activities. Eur J Pharmacol 2010; 638: 108-14.
51. Polizio AH, Pena C. Effects of angiotensin II type 1 receptor blockade on the oxidative stress in spontaneously hypertensive rat tissues. Regul Pept 2005; 128: 1-5.
52. Polizio AH, Gironacci MM, Tomaro ML, Pena C. Angiotensin-(1-7) blocks the angiotensin II-stimulated superoxide production. Pharmacol Res 2007; 56: 86-90.
53. da Silveira KD, Coelho FM, Vieira AT, et al. Anti-inflammatory effects of the activation of the angiotensin-(1-7) receptor, MAS, in experimental models of arthritis. J Immunol 2010; 185: 5569-76.
54. Sampaio WO, Henrique de Castro C, Santos RA, Schiffrin EL, Touyz RM. Angiotensin-(1-7) counterregulates angiotensin II signaling in human endothelial cells. Hypertension 2007; 50: 1093-8.
55. Sampaio WO, Souza dos Santos RA, Faria-Silva R, da Mata Machado LT, Schiffrin EL, Touyz RM. Angiotensin-(1-7) through receptor Mas mediates endothelial nitric oxide synthase activation via Akt-dependent pathways. Hypertension 2007; 49: 185-92.
56. Harman D. Aging: a theory based on free radical and radiation chemistry. J Gerontol 1956; 11: 298-300.
57. Dal-Ros S, Zoll J, Lang AL, et al. Chronic intake of red wine polyphenols by young rats prevents aging-induced endothelial dysfunction and decline in physical performance: Role of NADPH oxidase. Biochem Biophys Res Commun 2011; 404: 743-9.
58. Dal-Ros S, Oswald-Mammosser M, Pestrikova T, et al. Losartan prevents portal hypertension-induced, redox-mediated endothelial dysfunction in the mesenteric artery in rats. Gastroenterology 2010; 138: 1574-84.
59. Basso A, Rossolini G, Piantanelli A, et al. Aging reversibility: from thymus graft to vegetable extract treatment--application to cure an age-associated pathology. Biogerontology 2005; 6: 245-53.
60. Basso N, Paglia N, Stella I, et al. Protective effect of the inhibition of the renin-angiotensin system on aging. Regul Pept 2005; 128: 247-52.
61. Stein S, Schafer N, Breitenstein A, et al. SIRT1 reduces endothelial activation without affecting vascular function in ApoE-/-mice. Aging (Albany NY) 2010; 2: 353-60.
62. Mukai Y, Shimokawa H, Higashi M, et al. Inhibition of reninangiotensin system ameliorates endothelial dysfunction associated with aging in rats. Arterioscler Thromb Vasc Biol 2002; 22: 1445-50.
63. Hostetter TH, Olson JL, Rennke HG, Venkatachalam MA, Brenner BM. Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation. Am J Physiol 1981; 241: F85-93.
64. Liern M, Dieguez SM, De Reyes V, Vallejos G, Canepa C. [The additive antiproteinuric effect of Enalapril and Losartan to normotensive patients with pathology proteinuria]. Nefrologia 2004; 24: 553-8.
65. Chansel D, Bizet T, Vandermeersch S, Pham P, Levy B, Ardaillou R. Differential regulation of angiotensin II and losartan binding sites in glomeruli and mesangial cells. Am J Physiol 1994; 266: F384-93.
66. Inserra F, Basso N, Ferder M, et al. Changes seen in the aging kidney and the effect of blocking the renin-angiotensin system. Ther Adv Cardiovasc Dis 2009; 3: 341-6.
67. Chang L, Karin M. Mammalian MAP kinase signalling cascades. Nature 2001; 410: 37-40.
68. Min LJ, Mogi M, Iwanami J, et al. Cross-talk between aldosterone and angiotensin II in vascular smooth muscle cell senescence. Cardiovasc Res 2007; 76: 506-16.
69. Laplante MA, Wu R, El Midaoui A, de Champlain J. NAD(P)H oxidase activation by angiotensin II is dependent on p42/44 ERKMAPK pathway activation in rat's vascular smooth muscle cells. J Hypertens 2003; 21: 927-36.
70. Ushio-Fukai M, Alexander RW, Akers M, Griendling KK. p38 Mitogen-activated protein kinase is a critical component of the redox-sensitive signaling pathways activated by angiotensin II. Role in vascular smooth muscle cell hypertrophy. J Biol Chem 1998; 273: 15022-9.
71. Lu C, Su LY, Lee RM, Gao YJ. Superoxide anion mediates angiotensin II-induced potentiation of contractile response to sympathetic stimulation. Eur J Pharmacol 2008; 589: 188-93.
72. Touyz RM, Yao G, Quinn MT, Pagano PJ, Schiffrin EL. p47phox associates with the cytoskeleton through cortactin in human vascular smooth muscle cells: role in NAD(P)H oxidase regulation by angiotensin II. Arterioscler Thromb Vasc Biol 2005; 25: 512-8.
73. Kim MK, Chung SW, Kim DH, et al. Modulation of age-related NF-kappaB activation by dietary zingerone via MAPK pathway. Exp Gerontol 2010; 45: 419-26.
74. Benigni A, Corna D, Zoja C, et al. Disruption of the Ang II type 1 receptor promotes longevity in mice. J Clin Invest 2009; 119: 524-30.
75. Munoz MC, Giani JF, Dominici FP. Angiotensin-(1-7) stimulates the phosphorylation of Akt in rat extracardiac tissues in vivo via receptor Mas. Regul Pept 2010; 161: 1-7.
76. Giani JF, Gironacci MM, Munoz MC, Pena C, Turyn D, Dominici FP. Angiotensin-(1-7) stimulates the phosphorylation of JAK2, IRS-1 and Akt in rat heart in vivo: role of the AT1 and Mas receptors. Am J Physiol Heart Circ Physiol 2007; 293: H1154-63.
77. Dias-Peixoto MF, Santos RA, Gomes ER, et al. Molecular mechanisms involved in the angiotensin-(1-7)/Mas signaling pathway in cardiomyocytes. Hypertension 2008; 52: 542-8.
78. Liang CS, Mao W, Liu J. Pro-apoptotic effects of anti-beta1-adrenergic receptor antibodies in cultured rat cardiomyocytes: actions on endoplasmic reticulum and the prosurvival PI3K-Akt pathway. Autoimmunity 2008; 41: 434-41.
79. Fernandez-Hernando C, Jozsef L, Jenkins D, Di Lorenzo A, Sessa WC. Absence of Akt1 reduces vascular smooth muscle cell migration and survival and induces features of plaque vulnerability and cardiac dysfunction during atherosclerosis. Arterioscler Thromb Vasc Biol 2009; 29: 2033-40.
80. Zhang X, Tang N, Hadden TJ, Rishi AK. Akt, FoxO and regulation of apoptosis. Biochim Biophys Acta 2011; 1813: 1978-86.
81. Santos RA, Castro CH, Gava E, et al. Impairment of in vitro and in vivo heart function in angiotensin-(1-7) receptor MAS knockout mice. Hypertension 2006; 47: 996-1002.
82. Stegbauer J, Lee DH, Seubert S, et al. Role of the renin-angiotensin system in autoimmune inflammation of the central nervous system. Proc Natl Acad Sci USA 2009; 106: 14942-7.
83. Abadir PM, Walston JD, Carey RM, Siragy HM. Angiotensin II type-2 receptors modulate inflammation through signal transducer and activator of transcription proteins 3 phosphorylation and TNFalpha production. J Interferon Cytokine Res 2011; 31: 471-4.
84. Muller DN, Mervaala EM, Schmidt F, et al. Effect of bosentan on NF-kappaB, inflammation, and tissue factor in angiotensin IIinduced end-organ damage. Hypertension 2000; 36: 282-90.
85. Suzuki Y, Ruiz-Ortega M, Lorenzo O, Ruperez M, Esteban V, Egido J. Inflammation and angiotensin II. Int J Biochem Cell Biol 2003; 35: 881-900.
86. Walter A, Etienne-Selloum N, Sarr M, Kane MO, Beretz A, Schini-Kerth VB. Angiotensin II induces the vascular expression of VEGF and MMP-2 in vivo: preventive effect of red wine polyphenols. J Vasc Res 2008; 45: 386-94.
87. Zhu K, Shen Q, Ulrich M, Zheng M. Human monocyte-derived dendritic cells expressing both chemotactic cytokines IL-8, MCP-1, RANTES and their receptors, and their selective migration to these chemokines. Chin Med J (Engl) 2000; 113: 1124-8.
88. Tsou CL, Peters W, Si Y, et al. Critical roles for CCR2 and MCP-3 in monocyte mobilization from bone marrow and recruitment to inflammatory sites. J Clin Invest 2007; 117: 902-9.
89. Garcia GE. ANG II receptor antagonists as modulators of macrophages polarization. Am J Physiol Renal Physiol 2010; 298: F868-9.
90. Hilgers KF, Hartner A, Porst M, et al. Monocyte chemoattractant protein-1 and macrophage infiltration in hypertensive kidney injury. Kidney Int 2000; 58: 2408-19.
91. Tsuchiya A, Nagotani S, Hayashi T, et al. Macrophage infiltration, lectin-like oxidized-LDL receptor-1, and monocyte chemoattractant protein-1 are reduced by chronic HMG-CoA reductase inhibition. Curr Neurovasc Res 2007; 4: 268-73.
92. Sagawa K, Nagatani K, Komagata Y, Yamamoto K. Angiotensin receptor blockers suppress antigen-specific T cell responses and ameliorate collagen-induced arthritis in mice. Arthritis Rheum 2005; 52: 1920-8.
93. Wang PX, Fan MQ, Huang CB, et al. Effect of losartan on slowing progression of chronic allograft nephropathy. Chin Med Sci J 2005; 20: 231-6.
94. Tylicki L, Biedunkiewicz B, Chamienia A, et al. Renal allograft protection with angiotensin II type 1 receptor antagonists. Am J Transplant 2007; 7: 243-8.
95. Esteban V, Lorenzo O, Ruperez M, et al. Angiotensin II, via AT1 and AT2 receptors and NF-kappaB pathway, regulates the inflammatory response in unilateral ureteral obstruction. J Am Soc Nephrol 2004; 15: 1514-29.
96. Matavelli LC, Huang J, Siragy HM. Angiotensin AT receptor stimulation inhibits early renal inflammation in renovascular hypertension. Hypertension 2011; 57(2): 308-13.
97. Okada H, Inoue T, Kikuta T, et al. A possible anti-inflammatory role of angiotensin II type 2 receptor in immune-mediated glomerulonephritis during type 1 receptor blockade. Am J Pathol 2006; 169: 1577-89.
98. Santos RA, Ferreira AJ, Simoes ESAC. Recent advances in the angiotensin-converting enzyme 2-angiotensin(1-7)-Mas axis. Exp Physiol 2008; 93: 519-27.
99. Ye M, Wysocki J, William J, Soler MJ, Cokic I, Batlle D. Glomerular localization and expression of Angiotensin-converting enzyme 2 and Angiotensin-converting enzyme: implications for albuminuria in diabetes. J Am Soc Nephrol 2006; 17: 3067-75.
100. Zhang H, Wada J, Hida K, et al. Collectrin, a collecting ductspecific transmembrane glycoprotein, is a novel homolog of ACE2 and is developmentally regulated in embryonic kidneys. J Biol Chem 2001; 276: 17132-9.
101. Mizuiri S, Hemmi H, Arita M, et al. Expression of ACE and ACE2 in individuals with diabetic kidney disease and healthy controls. Am J Kidney Dis 2008; 51: 613-23.
102. Ingelfinger JR. Angiotensin-converting enzyme 2: implications for blood pressure and kidney disease. Curr Opin Nephrol Hypertens 2009; 18: 79-84.
103. Reich HN, Oudit GY, Penninger JM, Scholey JW, Herzenberg AM. Decreased glomerular and tubular expression of ACE2 in patients with type 2 diabetes and kidney disease. Kidney Int 2008; 74: 1610-6.
104. Zhang J, Noble NA, Border WA, Huang Y. Infusion of angiotensin-(1-7) reduces glomerulosclerosis through counteracting angiotensin II in experimental glomerulonephritis. Am J Physiol Renal Physiol 2010; 298: F579-88.
105. Ellefson DD, diZerega GS, Espinoza T, Roda N, Maldonado S, Rodgers KE. Synergistic effects of co-administration of angiotensin 1-7 and Neupogen on hematopoietic recovery in mice. Cancer Chemother Pharmacol 2004; 53: 15-24.
106. Esteban V, Heringer-Walther S, Sterner-Kock A, et al. Angiotensin-(1-7) and the g protein-coupled receptor MAS are key players in renal inflammation. PLoS One 2009; 4: e5406.
107. Platten M, Youssef S, Hur EM, et al. Blocking angiotensinconverting enzyme induces potent regulatory T cells and modulates TH1-and TH17-mediated autoimmunity. Proc Natl Acad Sci USA 2009; 106: 14948-53.
108. Lanz TV, Ding Z, Ho PP, et al. Angiotensin II sustains brain inflammation in mice via TGF-beta. J Clin Invest 2010; 120: 2782-94.
109. Dalbeth N, Edwards J, Fairchild S, Callan M, Hall FC. The nonthiol angiotensin-converting enzyme inhibitor quinapril suppresses inflammatory arthritis. Rheumatology (Oxford) 2005; 44: 24-31.
110. Artz MA, Hilbrands LB, Borm G, Assmann KJ, Wetzels JF. Blockade of the renin-angiotensin system increases graft survival in patients with chronic allograft nephropathy. Nephrol Dial Transplant 2004; 19: 2852-7.
111. Cruzado JM, Rico J, Grinyo JM. The renin angiotensin system blockade in kidney transplantation: pros and cons. Transpl Int 2008; 21: 304-13.
112. Montanaro D, Gropuzzo M, Tulissi P, et al. Renoprotective effect of early inhibition of the renin-angiotensin system in renal transplant recipients. Transplant Proc 2005; 37: 991-3.
113. Heinze G, Mitterbauer C, Regele H, et al. Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation. J Am Soc Nephrol 2006; 17: 889-99.
114. Stigant CE, Cohen J, Vivera M, Zaltzman JS. ACE inhibitors and angiotensin II antagonists in renal transplantation: an analysis of safety and efficacy. Am J Kidney Dis 2000; 35: 58-63.
115. Mackenzie HS, Ziai F, Nagano H, et al. Candesartan cilexetil reduces chronic renal allograft injury in Fisher-->Lewis rats. J Hypertens Suppl 1997; 15: S21-5.
116. Paul L, Muralidharan J, Benediktsson H. Glomerulosclerosis in kidney transplants: pathophysiologic mechanisms. Transplant Proc 1996; 28: 480-1.
117. el-Agroudy AE, Hassan NA, Foda MA, et al. Effect of angiotensin II receptor blocker on plasma levels of TGF-beta 1 and interstitial fibrosis in hypertensive kidney transplant patients. Am J Nephrol 2003; 23: 300-6.
118. Campistol JM, Inigo P, Jimenez W, et al. Losartan decreases plasma levels of TGF-beta1 in transplant patients with chronic allograft nephropathy. Kidney Int 1999; 56: 714-9.
119. Fischereder M. Chemokines and chemokine receptors in renal transplantation--from bench to bedside. Acta Physiol Hung 2007; 94: 67-81.
120. Szabo A, Lutz J, Schleimer K, et al. Effect of angiotensinconverting enzyme inhibition on growth factor mRNA in chronic renal allograft rejection in the rat. Kidney Int 2000; 57: 982-91.
121. Ziai F, Nagano H, Kusaka M, et al. Renal allograft protection with losartan in Fisher-->Lewis rats: hemodynamics, macrophages, and cytokines. Kidney Int 2000; 57: 2618-25.
122. Hiremath S, Fergusson D, Doucette S, Mulay AV, Knoll GA. Renin angiotensin system blockade in kidney transplantation: a systematic review of the evidence. Am J Transplant 2007; 7: 2350-60.
123. Dragun D, Muller DN, Brasen JH, et al. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med 2005; 352: 558-69.